Intensified insulin dosing along with more frequent BG monitoring or potentially using continuous glucose monitoring devices varied from non-COVID-19 patients could assist in maintaining adequate time in the range of blood glucose level (70–150 mg/dL) and thus, improve ICU outcomes. The gene discussed is INS; the disease is COVID-19.